Table 2.
Docking scores of inhibitors in clinical trials or in use of COVID-19 treatment.
| Molecule | Score | Molecule | Score | Molecule | Score |
|---|---|---|---|---|---|
| Danoprevir | −8.93 | Ritonavir | −7,20 | Pirfenidone | −5,86 |
| Nelfinavir | −8,92 | Camostat | −6,91 | Triazavirin | −5,52 |
| Ebastine | −8,47 | Chloroquine | −6,89 | Azvudine | −5,38 |
| Baloxavir_marboxil | −8,23 | Cobicistat | −6,80 | Fingolimod | −5,10 |
| Losartan | −8,14 | Darunavir | −6,73 | Emtricitabine | −4,94 |
| Methylprednisolone | −8,08 | Remdesivir | −6,68 | Ribavirin | −4,48 |
| Ivermectin | −8,07 | Oseltamivir | −6,41 | Tenofovir | −4,35 |
| Ruxolitinib | −8,04 | Hydroxychloroquine | −6,37 | Favipiravir | −4,21 |
| Lopinavir | −7,90 | Dipyridamole | −6,22 | Acetylcysteine | −3,74 |
| Umifenovir | −7,65 | Tranilast | −6,17 | ||
| Thalidomide | −7,26 | Azithromycin | −6,15 |